@article{JTD28670,
author = {Motoko Tachihara and Yoshihiro Nishimura},
title = {Who will suffer from hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors},
journal = {Journal of Thoracic Disease},
volume = {11},
number = {Suppl 9},
year = {2019},
keywords = {},
abstract = {The development of immunotherapy has resulted in a paradigm shift for the treatment of advanced non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors (ICIs) [i.e., programmed cell death 1 (PD-1)] and programmed cell death ligand 1 (PD-L1 inhibitors) are particularly important in the treatment of NSCLC, which is associated with poor prognosis. These agents have become a cornerstone of lung cancer treatment.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/28670}
}